Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03434262CT.gov SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Ependymoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sonidegib (this asset) | St. Jude Children's Research Hospital | P1 | CC · 47 |
| Lopinavir | Case Comprehensive Cancer Center | P2 | CCC |
| NORVIR | Case Comprehensive Cancer Center | P2 | CCC |
| Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) | Pediatric Brain Tumor Consortium | P2 | CCC |
| axl1717 | Rush University Medical Center | P1/2 | CCC |
| Lapatinib | National Cancer Institute (NCI) | P1 | CC |
| Trametinib | St. Jude Children's Research Hospital | P1 | CC |
| Therapeutic Allogeneic Lymphocytes | City of Hope Medical Center | P1 | CC |
| Ribociclib | St. Jude Children's Research Hospital | P1 | CC |
+4 more in the Anaplastic Ependymoma cohort
Other indications for Sonidegib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Leukemia | — | P2 | B · 57 |
| Medulloblastoma | — | P1 | CCC · 54 |
| Hepatocellular Carcinoma | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- LopinavirCase Comprehensive Cancer CenterCCC
- NORVIRCase Comprehensive Cancer CenterCCC
- Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate)Pediatric Brain Tumor ConsortiumCCC
- axl1717Rush University Medical CenterCCC
- LapatinibNational Cancer Institute (NCI)CC
Citation
Floatz Terminal. Sonidegib in Anaplastic Ependymoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sonidegib-anaplastic-ependymoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →